Heghine Khachatryan: When to Test for Thrombophilia After VTE

Heghine Khachatryan, Editor-in-Chief of Hemostasis Today, Head of Hemophilia and Thrombosis Center at Yeolyan Hematology and Oncology Center, shared a post on LinkedIn:

”Thrombophilia testing in VTE: test selectively, not routinely

Thrombophilia testing after venous thromboembolism (VTE) should not be performed as a routine ‘panel for everyone.’

The key question is simple: will the result change clinical management?

Testing may be particularly relevant in selected patients with unprovoked or recurrent VTE at a young age, thrombosis at unusual sites, a strong family history, hormone-associated thrombosis, recurrent pregnancy loss when antiphospholipid syndrome is suspected, or clinical features suggesting an underlying myeloproliferative neoplasm.

The diagnostic approach should also consider timing. Protein C, protein S and antithrombin levels can be altered during acute thrombosis, pregnancy and anticoagulant therapy. DOACs and vitamin K antagonists may interfere with several functional coagulation assays and lupus anticoagulant testing. In contrast, genetic testing for Factor V Leiden and prothrombin G20210A is not affected by anticoagulation.

A positive thrombophilia result does not automatically mean lifelong anticoagulation. Treatment duration should be individualized according to the type of thrombophilia, whether the VTE was provoked or unprovoked, recurrence risk, bleeding risk and the patient’s clinical context.

Particular attention is required for antiphospholipid syndrome (APS). In patients with high-risk APS—especially triple-positive APS—vitamin K antagonists remain the preferred long-term anticoagulant strategy, while DOACs are generally avoided.

Equally important is knowing when not to test. Routine thrombophilia screening before major surgery, prolonged immobilization, initiation of combined oral contraceptives in individuals without a relevant personal or family history, cancer-associated VTE, or indiscriminate screening of healthy relatives usually provides little clinical benefit.

The principle is therefore not ‘test more,’ but ‘test smarter’: thrombophilia testing is most valuable when the result can meaningfully influence recurrence-risk assessment, anticoagulation strategy, pregnancy management or counseling of the patient and family.”

Archives of Cardiovascular Diseases shared a post on LinkedIn about a recent article by Elena-Mihaela Cordeanu et al., published in Archives of Cardiovascular Diseases, adding:

”In patients with venous thromboembolism (VTE), thrombophilia testing should be selective and reserved for situations where the result may change management, according to a practical review published in Archives of Cardiovascular Diseases.

In this review of current international guidelines, Cordeanu et al. propose a clinical decision algorithm built on three sequential questions — when to test, how to test and how to interpret results — and stratify anticoagulation duration by recurrence risk: 3–4 percent per year for heterozygous factor V Leiden or prothrombin G20210A, versus 8–10 percent per year for antithrombin deficiency, for which extended or indefinite anticoagulation is strongly favoured.”

Title: Thrombophilia testing in venous thromboembolism: When, who and why it matters. A practical review

Authors: Elena-Mihaela Cordeanu, Corina Mirea, Camille Zamperini, Solène Brouder, Dominique Stephan

Stay updated on all scientific advances with Hemostasis Today.